These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33440374)

  • 21. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
    PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
    Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
    J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD-High Study).
    Trikha M; Sarkar L; Dhanawat A; Syed N; Gujarathi H; Vora M; Sivakumar Raja AS; Bhargava P; Ramaswamy A; Mandavkar S; Saklani A; Kaushal RK; Bal M; Shetty O; Yadav S; Ostwal V
    JCO Glob Oncol; 2024 Aug; 10():e2400141. PubMed ID: 39159410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of corticosteroid use during anti-PD1 treatment.
    Pan EY; Merl MY; Lin K
    J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
    Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
    Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
    De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
    J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
    Cybulska-Stopa B; Pacholczak-Madej R; Kamińska-Winciorek G; Ziętek M; Czarnecka AM; Piejko K; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Rolski J; Sałek-Zań A; Gajewska-Wicher K; Drosik-Kwaśniewska A; Rogala P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
    Immunotherapy; 2021 Mar; 13(4):297-307. PubMed ID: 33353420
    [No Abstract]   [Full Text] [Related]  

  • 30. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
    Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
    J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
    Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
    Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
    Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
    J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
    Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Claps M; Chiellino S; Zampiva I; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Cerbone L; Antonuzzo L; Roviello G
    Front Immunol; 2024; 15():1361010. PubMed ID: 39034992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    Waterhouse DM; Garon EB; Chandler J; McCleod M; Hussein M; Jotte R; Horn L; Daniel DB; Keogh G; Creelan B; Einhorn LH; Baker J; Kasbari S; Nikolinakos P; Babu S; Couture F; Leighl NB; Reynolds C; Blumenschein G; Gunuganti V; Li A; Aanur N; Spigel DR
    J Clin Oncol; 2020 Nov; 38(33):3863-3873. PubMed ID: 32910710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.